Harmony Biosciences Management Inc.

Fragile X Syndrome

Harmony Biosciences Management Inc. focuses its clinical research on Fragile X Syndrome, a hereditary neurodevelopmental disorder associated with intellectual and behavioural impairment in children, adolescents, and young adults. The sponsor’s studies address symptom management in this inherited condition.

  • Neurodevelopmental disorders
  • Inherited genetic conditions
  • Intellectual and behavioural development

Its research activity is concentrated in the United States, with currently recruiting studies involving paediatric and young adult populations affected by Fragile X Syndrome.

Behavioural Symptom Management

The sponsor is actively involved in clinical research targeting the behavioural symptoms linked to Fragile X Syndrome. This area reflects interest in improving day-to-day functioning and symptom control across developmental stages.

  • Behavioural symptoms
  • Paediatric neuropsychiatry
  • Developmental symptom control

Research in this domain includes patients from early childhood through young adulthood, with an emphasis on clinical outcomes relevant to behavioural impairment.

Long-term Safety and Tolerability

Harmony Biosciences Management Inc. also supports research evaluating the long-term safety and tolerability of treatment in Fragile X Syndrome. The sponsor’s clinical interest includes extended observation of treatment use over time in a chronic genetic disorder.

  • Long-term treatment safety
  • Tolerability monitoring
  • Chronic disorder management

This work is relevant to ongoing care in a persistent neurodevelopmental condition where sustained symptom management is clinically important.

Transdermal Therapeutic Delivery

The sponsor’s studies include interest in transdermal gel administration as a route for treatment in Fragile X Syndrome. This places emphasis on skin-applied therapy within a rare disease setting.

  • Transdermal gel formulations
  • Dermal drug delivery
  • Rare disease therapeutics

Clinical activity in this area links formulation-based treatment with the management of neurodevelopmental symptoms in a genetically defined population.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects and Safety of ZYN002 Gel for Children, Adolescents, and Young Adults with Fragile X Syndrome

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Ireland
  • Study on Long-Term Safety of ZYN002 Gel for Children, Adolescents, and Young Adults with Fragile X Syndrome

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Ireland